Showing 5711-5720 of 8844 results for "".
- With LifeCell Acquisition, Allergan Enters Regenerative Medicine Realmhttps://practicaldermatology.com/news/with-lifecell-acquisition-allergan-enters-regenerative-medicine-realm/2458341/Allergan plc has acquired the regenerative medicine company LifeCell for $2.9 billion in cash, subject to customary adjustments, Allergan reports. This acquisition combines LifeCell's products ALLODERM® and STRATTICETM tissue matrices commonly use
- Sandoz Acquires AmLactin Brandhttps://practicaldermatology.com/news/sandoz-acquires-amlactin-brand/2458342/Sandoz today announced that it has acquired the AmLactin® family of skin care brands from Minnesota-based pharmaceutical company Upsher-Smith Laboratories, Inc.
- Points Group and Dermatology Authority Launch the Derm Toolkit: A Revolutionary Service and Product Line for Dermatology Practiceshttps://practicaldermatology.com/news/points-group-and-dermatology-authority-launch-the-derm-toolkit-a-revolutionary-service-and-product-line-for-dermatology-practices/2458346/Points Group and Dermatology Authority are excited to announce the launch of the Derm Toolkit, an online portal that provides dermatology practices with a comprehensive set of tools and services to operate more effectively and grow their practices. Over the next four months, the
- FDA Approved Eucrisa (Crisaborole) for ADhttps://practicaldermatology.com/news/fda-approved-eucrisa-crisaborole-for-ad/2458344/The U.S. Food and Drug Administration approved Eucrisa (crisaborole) ointment to treat mild-to-moderate eczema in patients two years of age and older. Eucrisa, applied topically twice daily, is a phosphodiesterase 4 (PDE-4) i
- Valeant Appoints William D. Humphries As EVP, Dermatologyhttps://practicaldermatology.com/news/valeant-appoints-william-d-humphries-as-evp-dermatology/2458348/Valeant Pharmaceuticals International, Inc. appointed William D. Humphries as Executive Vice President, Dermatology, effective January 2, 2017. Mr. Humphries will join Valeant's Executive Committee, reporting directly to
- AnaptysBio, Inc.'s IL-33-Blocker Cleared for Phase 2a Trials in AD, Peanut Allergyhttps://practicaldermatology.com/news/anaptysbio-incs-il-33-blocker-cleared-for-phase-2a-trials-in-ad-peanut-allergy/2458347/The United Kingdom Medicines and Healthcare Products Regulatory Agency has green lighted a Phase 2a clinical trial for AnaptysBio, Inc.’s ANB020 for the treatment of adults with moderate-to-severe atopic dermatitis. The United States Food and Drug Ad
- Galderma's Restylane Refyne and Restylane Defyne Fillers FDA Approved for “Laugh Lines”https://practicaldermatology.com/news/galdermas-restylane-refyne-and-restylane-defyne-fillers-fda-approved-for-laugh-lines/2458349/The FDA approved two new products for the treatment of nasolabial folds (NLF) or “laugh lines,” in patients over the age of 21—Galderma's Restylane Refyne and Restylane Defyne. Restylane Refyne was approved for the treatment of moderate to severe facial wrinkl
- PuraCap Rolls Out Two New Acne Productshttps://practicaldermatology.com/news/puracap-rolls-out-two-new-acne-products/2458351/PuraCap Pharmaceutical LLC is rolling out two new acne products, Eptex Controlled Release Acne Wash and Eptex Controlled Release Acne Relief Lotion. Available through healthcare professionals, the products utilize a controlled release Intelli-Tar
- CDC Study: Banning Indoor Tanning Among Minors Will Save Lives, Moneyhttps://practicaldermatology.com/news/banning-indoor-tanning-among-minors-will-save-lives-money/2458354/An age restriction on indoor tanning could save thousands of lives and millions of dollars, according to new research published online in the Journal of the American Academy of Dermatology. In December 2015, the U.S. Food and Drug Administration
- Study: Anxiety Linked to Skin Diseasehttps://practicaldermatology.com/news/study-anxiety-linked-to-skin-disease/2458359/Anxiety disorders tend to be followed by skin diseases, according to psychologists at the University of Basel in Switzerland and Ruhr University Bochum in Germany. The study, which appears in the journa